LONDON, May 2 (Reuters) - Novo Nordisk has

seen the price of its hugely popular weight-loss drug Wegovy and

diabetes drug Ozempic fall in the United States as volumes and

competition have increased, a senior executive said on Thursday.

Wegovy prices in the United States were "slightly down" in

the first quarter and Novo expects further decreases through the

rest of 2024, Chief Financial Officer Karsten Munk Knudsen said

on a call with media.

On Ozempic, "we do see continued reduction in price" in the

U.S. market, Knudsen later said on an investor call, also citing

increased volumes and competition.

Ozempic contains the same active ingredient as Wegovy

but is a type 2 diabetes treatment.

The comments came after the Danish drugmaker raised its

full-year outlook due to explosive demand for the weekly

injection.